Literature DB >> 25220049

Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease.

Hicham I Cheikh Hassan1, Frank Brennan2, Gemma Collett3, Elizabeth A Josland3, Mark A Brown3.   

Abstract

CONTEXT: Pruritus and restless legs syndrome (RLS) frequently affect patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD), impacting the quality of life. Gabapentin (1-aminomethyl cyclohexane acetic acid) alleviates these symptoms in hemodialysis (HD) patients, but data are lacking for patients on the conservative pathway.
OBJECTIVES: To determine the safety and effectiveness of gabapentin for pruritus or RLS in conservatively managed patients (n = 34) with CKD and ESKD.
METHODS: This was a single-center retrospective cohort study. We compared dosing and side effects in 34 CKD/ESKD patients with similar patients receiving HD (n = 15).
RESULTS: Forty-four percent of conservatively managed patients complained of RLS and/or pruritus; 18% were excluded for a nonuremic cause of symptom. Thirty-four patients were included in the final analysis. The most common starting daily dose of gabapentin was the equivalent of 50 mg (44.1%) or 100 mg (38.2%) daily, with the median daily dose of 100 mg (range 39-455 mg). Side effects occurred in 47% of patients, with 17% discontinuing gabapentin. Gabapentin reduced symptoms of pruritus (P < 0.001) and RLS (P < 0.05). There was no statistical difference when comparing HD and conservatively managed patients for daily starting dose (P = 0.88), median dose (P = 0.84), and final dose (P = 0.18). Patients conservatively managed were more likely to manifest side effects compared with HD patients (47.1% vs. 14.3%, P = 0.023). Dose was not found to be a factor associated with side effects in univariate analysis.
CONCLUSION: Gabapentin is a viable treatment for conservatively managed CKD and ESKD patients with pruritus and/or RLS, but side effects are common. Gabapentin should be used with caution although higher doses do not appear to be a factor associated with side effects.
Copyright © 2015 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gabapentin; conservative management; dialysis; end-stage kidney disease; pruritus; restless legs syndrome

Mesh:

Substances:

Year:  2014        PMID: 25220049     DOI: 10.1016/j.jpainsymman.2014.08.010

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  5 in total

Review 1.  Pruritus in Kidney Disease.

Authors:  Sara A Combs; J Pedro Teixeira; Michael J Germain
Journal:  Semin Nephrol       Date:  2015-07       Impact factor: 5.299

Review 2.  Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease.

Authors:  Michele A Faulkner
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

3.  Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1.

Authors:  Phuong Tran; Hee-Doo Yoo; Lien Ngo; Hea-Young Cho; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-10-10       Impact factor: 2.745

4.  Pain management in patients with chronic kidney disease and end-stage kidney disease.

Authors:  Payel J Roy; Melanie Weltman; Laura M Dember; Jane Liebschutz; Manisha Jhamb
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-11       Impact factor: 3.416

Review 5.  Gabapentin for uremic pruritus in hemodialysis patients: a qualitative systematic review.

Authors:  Torey Lau; Sharon Leung; Wynnie Lau
Journal:  Can J Kidney Health Dis       Date:  2016-03-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.